Triple negative breast cancer is responsive to chemotherapy but chemotherapy might be underused in some patient subgroups. Women with primary invasive, nonmetastatic breast cancer were recruited in Washington, DC, and Detroit. Chemotherapy uptake was greater for black than for white women (48.3% vs. 11.7%; P [ .01) and for women without (vs. with) health care discrimination (35% vs. 25%; P [ .04). Future investigations are necessary to assess whether the noninitiation and/or noncompletion of chemotherapy is clinically warranted. Background: Triple negative breast cancer (TNBC) tumors are estrogen receptor-negative, progesterone receptornegative, and human epidermal growth factor-negative. TNBC is responsive to chemotherapy, but chemotherapy might be underused in some patient subgroups. The goal of the present study was to characterize the patterns of chemotherapy use (uptake and completion) in TNBC patients. Patients and Methods: Women with primary invasive, nonmetastatic breast cancer were recruited in Washington, DC, and Detroit. Data were collected using a standardized telephone survey that captured sociocultural and health care process factors. Clinical data were abstracted from the medical records. We used c 2 tests to access the association between the receipt of chemotherapy use (initiation and completion) and categorical variables, and t tests were used for continuous variables. Logistic regression models were used to evaluate the factors associated with chemotherapy uptake. Results: Women with TNBC (16% of sample) were more likely to be black than white (68% vs. 32%; P < .05). Among women with TNBC, 60% underwent chemotherapy. Chemotherapy uptake was greater for black than for white women (48.3% vs. 11.7%; P ¼ .01) and in women without (vs. with) healthcare discrimination (35% vs. 25%; P ¼ .04). In multivariable models, only race was associated with the receipt of chemotherapy. Black women were more likely to receive chemotherapy than were white women. The odds ratio of receiving chemotherapy by race was 4.1 (95% confidence interval, 1.3-13.1). Each 1-year increase in age was associated with a lower likelihood of chemotherapy completion (odds ratio, 0.9; 95% confidence interval, 0.826-0.981; P ¼ .02). Women with at least some college were less likely to complete chemotherapy than were those with other education levels (P ¼ .02). Conclusion: A substantial number of TNBC patients failed to receive and/or complete chemotherapy. Differences in chemotherapy uptake by race and sociocultural factors diminished in multivariable models but age and stage remained significant. Suboptimal treatment among women with TNBC could contribute to adverse outcomes. Future investigations are necessary to assess whether the noninitiation and/or noncompletion of chemotherapy is clinically warranted.
Introduction
Triple negative breast cancer (TNBC) cases account for 10% to 17% of all breast cancer cases and are defined by the lack of expression of estrogen receptors (ERs), progesterone receptors (PRs) and human epidermal growth factor receptor (HER2). 1 The risk of TNBC appears to be greater for women who are obese, those with a greater number of births, and those who are physically inactive. 1 Women with a diagnosis of TNBC have a poorer prognosis and inferior outcomes compared with women with other subtypes of breast cancer. 2 No standard targeted therapies are available for TNBC, although chemotherapy has been shown to be effective against these tumors. 3 Neoadjuvant chemotherapy has been used to improve subsequent surgical intervention, and TNBC patients, in particular, have responded well to neoadjuvant therapy, with pathologic complete response rates commonly greater than those for patients with other breast tumor types. 4 However, more than one half of TNBC patients will not achieve a pathologic complete response and will have a very poor prognosis. 4 Thus, chemotherapy has been recommended for most women with TNBC. 5 Outside of clinical trial settings, relatively little is known about the patterns of chemotherapy use for TNBC patients. Furthermore, because most reports have relied on administrative databases 6 or retrospective analyses, 7 few have included patient-reported factors such as the ratings of communication about chemotherapy among women with TNBC. The present study aimed to describe the characteristics of women with a diagnosis of TNBC and to assess the influence of clinical, sociodemographic, and health care factors on chemotherapy use among TNBC patients. These findings might identify potentially mutable targets to improve cancer prevention and control in these patients.
Patients and Methods

Setting and Population
The details of the study have been previously reported. 8 In brief, women with a diagnosis of breast cancer were recruited from hospitals in Washington, DC, and Detroit and by community outreach from July 2006 to April 2011. The institutional review board at all institutions approved the study procedures. We included black and white women aged > 21 years with a diagnosis of invasive nonmetastatic disease for whom systemic adjuvant therapy would be considered with curative intent. The exclusion criteria were ductal and lobular carcinoma in situ, distant metastasis, recurrent disease, second primary cancer, non-English speaking, race other than black or white, or failure to provide informed consent. Of the 477 eligible women, 395 (82.8%) agreed to participate. Of these 395 women, 36 were excluded from the subsequent analyses because of missing clinical data. The final analytic sample included 359 women.
Data Collection
Potentially eligible hospital patients were identified from surgery logs, pathology reports, and electronic appointment systems. Those patients responding to the outreach recruitment were selfreferred to the study. Clinical research assistants confirmed eligibility and obtained consent for interviews and medical record reviews. Interviews were conducted centrally by trained staff using a standardized computer-assisted telephone survey. On average, the interviews lasted for about 50 minutes. The medical records were monitored for 18 months after the interview. Participants received a $25 gift card.
Measures
Chemotherapy use was obtained from the medical records and assessed according to chemotherapy initiation (yes vs. no) of any chemotherapy regimen 8 and chemotherapy completion (yes vs. no).
The secondary measures used to describe chemotherapy were the interval to chemotherapy initiation (in days) and chemotherapy delay (> 90 days). The interval to chemotherapy initiation was measured for the patients who initiated therapy as the number of days between the patient's last definitive surgery and her first cycle of adjuvant chemotherapy. The third outcome, initiation delay, was defined as > 90 days from surgery to the start of chemotherapy in accordance with reports that have linked this length of delay to decrements in survival. 9 The clinical factors included ER status (positive vs. negative), surgery type (lumpectomy vs. mastectomy), nodal status (positive vs. negative), pathologic tumor size, and human epidermal growth factor receptor (HER2/neu) status (positive vs. negative). 9 Comorbidity was measured using the Charlson comorbidity index score. 10 The body mass index was calculated from the data in the medical records and categorized as either obese (> 30 kg/m 2 ) or nonobese (< 30 kg/m 2 ). 11 The participants were grouped according to treatment indication status (indicated vs. considered) using the tumor characteristics and National Comprehensive Cancer Network practice guidelines.
12
The demographic variables recorded were age, education, marital status, and employment status. Factors related to patientcentered interactions with physicians were collected by patient self-report. The Makoul communication scale (7 items) was adapted to assess the self-reported communication with oncologists regarding chemotherapy (overall Cronbach's a, 0.83). 13 To measure the patients' level of trust in their oncologist, we adapted items from the Primary Care Assessment Survey, which has shown good reliability (0.86) in cancer settings and was reliable in our sample (overall Cronbach's a, 0.81).
14 Perceived health care discrimination was assessed using the Race-based Experiences scale and was categorized as any versus none. 15 The Group-based Medical Mistrust Scale measured the perceived level of group distrust in health care systems and practices (Cronbach's a, 0.84). 16 The sociocultural factors included religiosity and chemotherapy attitudes. Religiosity was measured using 9 items from Lukwago et al 17 (overall Cronbach's a, 0.95) and was dichotomized at the median, with higher scores indicating greater religiosity. To measure the attitudes about chemotherapy, 18 items were used captured women's perceptions about the efficacy of therapy ("chemotherapy does not help you live longer") and about side effects ("the side effects of chemotherapy are worse than the disease"; overall Cronbach's a, 0.60). Scores above the median reflected positive attitudes and those below, negative attitudes.
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Statistical Analysis
Descriptive statistics were used to evaluate the variable characteristics. We used t tests and c 2 tests to assess bivariate relationships between chemotherapy initiation and the study variables. Stepwise logistic regression analysis was used to model initiation. The selection of variables for inclusion in the regression models was determined by bivariate significance (P < .05). We tested for the presence of interactions between the variables of interest and race. The goodness-of-fit and predictive capability of the logistic models were evaluated using the Hosmer-Lemeshow test and the C-statistic measure. Post hoc analyses were used to compare the receipt of all treatments by race among women with TNBC. All analyses were conducted using SAS, version 9.
Results
Of all the patients recruited, 75% had ER þ , 66% had PR þ , and 15% had HER2 þ disease. The prevalence of TNBC in all patient recruited was 16%. Women diagnosed with TNBC tended to be black (vs. white; P ¼ .09). The mean age of the patients was 55 years, and 64% were > 50 years old. Women with TNBC had larger tumors than those with other subtypes (P < .05). No differences were noted in positive versus negative nodal status or the number of positive nodes (P > .05; Table 1 ). As expected, women with TNBC were more often indicated to undergo chemotherapy compared with their non-TNBC counterparts (P < .05). Also, more women with TNBC underwent chemotherapy than did those without TNBC (P ¼ .0003). The interval to chemotherapy was similar for those with TNBC (mean AE standard deviation, 72.4 AE 78.0 days) and without TNBC (mean AE standard deviation, 73.1 AE 51.4; P > .05; Table 1 ). The patterns of surgery and radiation were also similar across the 2 groups. No significant differences were found in the interval to definitive surgery for women with and without TNBC (P > .05). The patterns of chemotherapy use among TNBC patients were also evaluated. Of the women diagnosed with TNBC, 60% underwent chemotherapy (25%, neoadjuvant; 75%, adjuvant). Of the regimens, 50% were anthracycline-based (anthracycline plus cyclophosphamide, 35%; anthracycline-cyclophosphamide-taxane, 15%), 10% were taxane-cyclophosphamide, 3% were taxane only, and the remaining were other combinations.
On univariate analysis, chemotherapy use was greater for black than for white women (70.7% vs. 36.8%), and the mean age of the women undergoing chemotherapy was slightly lower (mean, 51.8 AE 11 years) than that of those not undergoing chemotherapy (mean, 58.2 AE 12.6 years; P ¼ .04). Most sociocultural factors were not associated with the receipt of chemotherapy. Perceptions of discrimination was the only significant sociocultural factor; women with greater perceptions of health care discrimination experienced a greater use of chemotherapy (P ¼ .04; Table 2 ).
For the multivariable stepwise logistic regression analysis to examine the factors associated with the receipt of chemotherapy, those variables significant at P < .05 were entered into the model. Only race was associated with the receipt of chemotherapy. Of the patients with TNBC, black women were more likely to receive chemotherapy than were white women. The odds ratio of undergoing chemotherapy by race was 4.1 (95% confidence interval, 1.3-13.1). Triple Negative Breast Cancer Chemotherapy
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The rate of chemotherapy completion was 72.2% among TNBC patients who initiated chemotherapy. Each 1-year increase in age was associated with a lower likelihood of chemotherapy completion (odds ratio, 0.9; 95% confidence interval, 0.826-0.981; P ¼ .02). Women with at least some college were less likely to complete chemotherapy than were women with other education levels (P ¼ .02). Of the women with TNBC, the average age of the white women was older than the age of the black women (58.5 vs. 52.3 years); however, the difference was not statistically significant (P ¼ .4638). No race differences were found for surgery type (lumpectomy vs. mastectomy; P ¼ .4311), radiation uptake (P ¼ .1715), or radiation with lumpectomy or mastectomy alone (P ¼ .3560; data not shown).
Discussion
To the best of our knowledge, the factors associated with receipt of chemotherapy in TNBC patients outside of clinical trials have not been well described. The present study has expanded the knowledge about TNBC patients' chemotherapy patterns by examining the sociocultural and health care factors and describing the chemotherapy completion rates. Although most women received chemotherapy, a notable proportion of women did not. Demographic factors such as age and education were associated with receipt of chemotherapy on univariate analysis, but race remained the most robust predictor on multivariable analysis. We examined a host of sociocultural and process of care factors that have been suggested to affect the uptake of systemic therapies (eg, medical mistrust, self-efficacy). However, most were not related to chemotherapy uptake for women with TNBC. Women who reported perceptions of health care discrimination were less likely to receive chemotherapy; however, this effect had diminished after controlling for other covariates.
The greater uptake of chemotherapy among black women with TNBC contradicts studies that have reported the lower receipt of systemic therapy or equivalent uptake of chemotherapy. 9 Most reports of chemotherapy use have not focused on women with TNBC, making comparisons of chemotherapy use across existing studies difficult. In an assessment of treatment in various breast cancer subtypes, Hassett et al 19 found that black women were more likely to receive the recommended chemotherapy (but less likely to undergo the recommended radiation and surgery) than were white women, which would support our findings in women with TNBC. Age, sociocultural influences, and/or patienteprovider interactions could also explain some of the differences we observed by race. For example, Morimoto et al, 20 and others, found that older age was associated with less chemotherapy use. Thus, one explanation for the greater rate of chemotherapy could have been differences in age distribution between and within racial groups, with black patients tending to be younger. Although the difference did not reach statistical significance, among women with TNBC in our sample, the average age for the white women was older than that of the black women (58.5 vs. 52.3 years). However, the difference was not statistically significant (P ¼ .463).
The black women in our study might have perceived that they were at high risk of recurrence and/or mortality. 8 Ashing-Giwa et al 21 found that "word-of-month" and cultural factors influenced cancer decisions in the black community. Given the high rates of breast cancer mortality among black women (in particular, in our Atlanta and Washington, DC, sites), chemotherapy and/or TNBC might be well known in these communities. Future studies that capture the influence of community norms, practices, and experiences will be useful. In addition to patient-level factors, process of care factors such as patienteprovider communication about chemotherapy might differ between blacks and whites, with reports suggesting that black patients desire more information from their providers than do white patients. 22 It is unclear whether the lower uptake of chemotherapy for white patients was clinically warranted, given that they had TNBC. Reports have suggested that black patients might have different communication preferences related to chemotherapy compared with their white counterparts. 8 Further investigation is needed to collect detailed information regarding patienteprovider communication and to empirically examine the decision-making processes among black and white cancer patients. Women with higher stage were more likely to complete chemotherapy. This might suggest that women with higher stage disease perceived their diagnosis to have more severity and that treatment outcomes would be equivocal compared with those with lower stage disease. 23 It is also possible that physicians were more persuasive in discussions about chemotherapy with women with higher stage disease. Post hoc analysis results suggested that women with higher stage reported greater communication about chemotherapy with their providers (P < .05). Triple Negative Breast Cancer Chemotherapy
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The prevalence of TNBC in the present sample (16%) was within the ranges reported in other studies. 6 Similar to other reports, women with TNBC had more aggressive tumor characteristics and more patients were black than white. 24 However, TNBC was not associated with weight status 25 ; we did not measure the waist-to-hip ratio, which might account for this difference. It is well known that patients with TNBC have an increased likelihood of distant recurrence and death compared with women with other types of breast cancer. 26 Despite advances in identifying potential biomarkers and their corresponding therapeutic compounds in the ongoing TNBC clinical trials, an effective and approved target therapy for these tumors is not yet available. 27 However, relatively little research has focused on assessing whether women indicated for chemotherapy actually receive it as one possible explanation for the observed outcomes among women with TNBC. Our findings suggest that not all women indicated to undergo chemotherapy complete it. Understanding the reasons for noncompletion will be important, in particular, because of the 36 women who initiated chemotherapy, 10 (28%) did not complete it.
Study Limitations
The present study had several strengths, including a high proportion of black patients, and the assessment of numerous sociocultural and health care process factors hypothesized to affect the receipt of cancer treatment. Nevertheless, the results should be interpreted in the light of several limitations. The experiences of the women in the present study might not represent the experiences of women who are uninsured, from rural regions, or with less education. Moreover, we did not have specific information about patienteprovider conversations, and some women might have elected to forgo chemotherapy because of input from their providers, preexisting conditions, or reasons not captured in our study. The providers were not interviewed; thus, we could not verify the conversations between providers and patients with TNBC. Future studies focusing on patienteprovider dyads might add to our understanding of the treatment patterns among TNBC patients. Understanding the effect of patienteprovider communication and how it might vary among women with TNBC could be useful. Communication about chemotherapy (risks and benefits) was not associated with chemotherapy uptake by TNBC patients, although it has been found to be associated with uptake of chemotherapy among women with 
Conclusion
Although more research is critical to better understand the problem from various perspectives, some actions might be warranted. First, patienteprovider discussions about the benefits of chemotherapy and the harms of noncompliance in the treatment of TNBC should occur early and throughout the treatment process. Upfront discussions about potential side effects and managing the side effects would also be useful. In addition, patient navigators might aide in helping support the timely receipt and completion of cancer care. 28 Finally, leveraging opportunities to engage caregivers either through conversation or the provision of materials might boost social support for patients and enable them to complete therapy. 29 Clinically-based interventions for the treatment of women with TNBC might contribute to some of the adverse outcomes in this group and warrant further examination. An important next step might be to examine the contribution of noncompliance to the risk of recurrence and/or mortality in women with TNBC.
Clinical Practice Points
TNBC is characterized as being clinically aggressive and displaying poor long-term survival. When studies have controlled for treatment in women with TNBC, 100% compliance has often been assumed; however, we found that a substantial number of women failed to receive it. Noncompliance with therapy is complex, and multilevel approaches are needed. Although more research is critical to better understand the problem from various perspectives, some actions might be warranted, including early and continuing patienteprovider discussions about the benefits of chemotherapy and harm of noncompliance; upfront discussions about the potential side effects and their management; patient navigators to help support the timely receipt and completion of cancer care; and leveraging opportunities to engage caregivers either by conversation or provision of materials to boost social support for patients and enable them to complete therapy. Clinically-based interventions to treat TNBC might contribute to some of the adverse outcomes and warrants further examination; thus, an important next step might be to examine the contribution of noncompliance to the risk of recurrence and/or mortality in women with TNBC.
